JP2022536364A - 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法 - Google Patents
操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法 Download PDFInfo
- Publication number
- JP2022536364A JP2022536364A JP2021573607A JP2021573607A JP2022536364A JP 2022536364 A JP2022536364 A JP 2022536364A JP 2021573607 A JP2021573607 A JP 2021573607A JP 2021573607 A JP2021573607 A JP 2021573607A JP 2022536364 A JP2022536364 A JP 2022536364A
- Authority
- JP
- Japan
- Prior art keywords
- cargo
- particles
- hevlp
- proteins
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title claims abstract description 314
- 238000000034 method Methods 0.000 title claims abstract description 109
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 72
- 101710188315 Protein X Proteins 0.000 claims abstract description 72
- 101710177291 Gag polyprotein Proteins 0.000 claims abstract description 34
- 101710125418 Major capsid protein Proteins 0.000 claims abstract description 33
- 239000012528 membrane Substances 0.000 claims abstract description 15
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 15
- 108091035707 Consensus sequence Proteins 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 241
- 108090000623 proteins and genes Proteins 0.000 claims description 105
- 102000004169 proteins and genes Human genes 0.000 claims description 103
- 102100034349 Integrase Human genes 0.000 claims description 71
- 238000010362 genome editing Methods 0.000 claims description 70
- 239000003153 chemical reaction reagent Substances 0.000 claims description 43
- 108091033409 CRISPR Proteins 0.000 claims description 36
- 230000004927 fusion Effects 0.000 claims description 29
- 210000000170 cell membrane Anatomy 0.000 claims description 24
- 230000007115 recruitment Effects 0.000 claims description 24
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 21
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 21
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 17
- 229910052725 zinc Inorganic materials 0.000 claims description 17
- 239000011701 zinc Substances 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 108020005004 Guide RNA Proteins 0.000 claims description 15
- 150000003384 small molecules Chemical class 0.000 claims description 11
- 108090000288 Glycoproteins Proteins 0.000 claims description 10
- 102000003886 Glycoproteins Human genes 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 108010089520 pol Gene Products Proteins 0.000 claims description 5
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 4
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 150000005829 chemical entities Chemical class 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims 15
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims 12
- 239000000126 substance Substances 0.000 abstract description 15
- 102100021696 Syncytin-1 Human genes 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 90
- 238000004519 manufacturing process Methods 0.000 description 80
- 238000004520 electroporation Methods 0.000 description 73
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 64
- 239000013612 plasmid Substances 0.000 description 32
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 30
- 101710159080 Aconitate hydratase A Proteins 0.000 description 27
- 101710159078 Aconitate hydratase B Proteins 0.000 description 27
- 101710105008 RNA-binding protein Proteins 0.000 description 27
- 241000713887 Human endogenous retrovirus Species 0.000 description 23
- 101710185494 Zinc finger protein Proteins 0.000 description 23
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 23
- 102000053602 DNA Human genes 0.000 description 22
- 238000001890 transfection Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 16
- 238000006471 dimerization reaction Methods 0.000 description 15
- 210000000172 cytosol Anatomy 0.000 description 13
- 238000005734 heterodimerization reaction Methods 0.000 description 13
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 12
- 229940123611 Genome editing Drugs 0.000 description 12
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 12
- 239000002105 nanoparticle Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 description 10
- 101710163270 Nuclease Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000447 dimerizing effect Effects 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 229920002873 Polyethylenimine Polymers 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 102000016914 ras Proteins Human genes 0.000 description 7
- 230000001177 retroviral effect Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 108090000565 Capsid Proteins Proteins 0.000 description 6
- 102100023321 Ceruloplasmin Human genes 0.000 description 6
- 101100091360 Homo sapiens RNPC3 gene Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- -1 etc.) Proteins 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102100034353 Integrase Human genes 0.000 description 5
- 241000209094 Oryza Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 108010078428 env Gene Products Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000008857 Ferritin Human genes 0.000 description 4
- 108050000784 Ferritin Proteins 0.000 description 4
- 238000008416 Ferritin Methods 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000034303 cell budding Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 230000017730 intein-mediated protein splicing Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009437 off-target effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108020001580 protein domains Proteins 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100034347 Integrase Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010026552 Proteome Proteins 0.000 description 3
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 3
- 101710146873 Receptor-binding protein Proteins 0.000 description 3
- 102100024544 SURP and G-patch domain-containing protein 1 Human genes 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- 238000010459 TALEN Methods 0.000 description 3
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 3
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000006780 non-homologous end joining Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108700038581 vectofusin-1 Proteins 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 2
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 2
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 101150078024 CRY2 gene Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101000733566 Homo sapiens Activity-regulated cytoskeleton-associated protein Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101000582767 Homo sapiens Regucalcin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000737052 Naso hexacanthus Species 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 238000010357 RNA editing Methods 0.000 description 2
- 230000026279 RNA modification Effects 0.000 description 2
- 102100030262 Regucalcin Human genes 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- 102000007451 Steroid Receptors Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108700022715 Viral Proteases Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 108010079872 activity regulated cytoskeletal-associated protein Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960002465 dabrafenib Drugs 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 102000044459 human CD47 Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001950 radioprotection Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 108010037253 syncytin Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZVEUWSJUXREOBK-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound NCC(O)=O.OC[C@H](N)C(O)=O ZVEUWSJUXREOBK-DKWTVANSSA-N 0.000 description 1
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 241000093740 Acidaminococcus sp. Species 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108700004991 Cas12a Proteins 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102100029698 Metallothionein-1A Human genes 0.000 description 1
- 101710196493 Metallothionein-1E Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000034778 micropinocytosis Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10051—Methods of production or purification of viral material
- C12N2740/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Abstract
Description
本出願は、2019年6月13日に出願された、米国特許出願第62/861,186号明細書の権利を主張するものである。上述の内容全体が参照により本明細書中に組み込まれる。
本発明は、米国国立衛生研究所(NIH)から交付された助成金番号GM118158に基づく政府の支援により行われた。政府は本発明について一定の権利を有する。
本明細書において、操作されたヒト内在性ウイルス様粒子(heVLP)であって、外側にリン脂質二重膜を含む膜、および膜の内側のheVLPのコアに配置されたカーゴ、例えば生体分子および/または化学カーゴを含み、非ヒトgagまたはpol由来のタンパク質を含まないheVLP、ならびに細胞へのカーゴの送達のためのその使用方法を記載する。
タンパク質ベースのカーゴを封入して送達するように操作されている従来のVLPは、一般的にはカーゴをINTまたはGAGポリプロテインと融合させる25~27、29、30、39、40。産生プラスミドDNAコンストラクトを一過性にトランスフェクションした後、これらのタンパク質融合体は、従来のVLP産生細胞株のサイトゾル内で翻訳され、gagマトリックスはアセチル化されて細胞膜に動員され、VLPが膜から細胞外に出芽する際に、gag融合体はVLP内に封入される(一過性のトランスフェクション用DNAも意図せずに封入される)。
heVLPは、少なくとも1つのプラスミドで一過性にトランスフェクションされたか、または産生細胞株のゲノムDNAに組み込まれたコンストラクトを安定的に発現している産生細胞株から産生される。いくつかの実施形態において、T1およびT3heVLPについて、単一のプラスミドをトランスフェクションに使用する場合、それは、ヒト内在性GAGまたは他の細胞膜動員ドメイン(例えば、表6に示す)と融合した、1つまたは複数のHERV由来の糖タンパク質(例えば、表1に示す)、1つまたは複数のHERV由来のGAGタンパク質、カーゴ(例えば、治療用タンパク質または遺伝子編集試薬、例えばジンクフィンガー、転写活性化因子様エフェクター(TALE)、および/またはCRISPRベースのゲノム編集/調節タンパク質および/またはRNP、例えば表2、3、4および5に記載される他のもの)、ならびに必要に応じてガイドRNAをコードする配列を含んでいるはずである。好ましくは、トランスフェクションには2~3個のプラスミドを用いる。これらの2~3個のプラスミドは、以下のものを含むことができる(任意の2つ以上を1つのプラスミドにおいて組み合わせ得る):
1. ヒト内在性GAGまたは他の細胞膜動員ドメインと融合した、治療用タンパク質またはゲノム編集試薬をコードする配列を含む、プラスミド。
2. 1つまたは複数のHERV由来の糖タンパク質(例えば、表1に列挙するもの)を含む、プラスミド。
3. 1つまたは複数のHERV由来のGAGタンパク質を含むプラスミド。
4. プラスミド1からのゲノム編集試薬が、1つまたは複数のガイドRNAを必要とする場合、プラスミド1におけるゲノム編集試薬に適切な1つまたは複数のガイドRNAを含むプラスミド。
好ましくは、トランスフェクションの36~48時間後、またはheVLPが産生細胞の培地中で最大濃度であるときに、細胞培養液の上清からheVLPを回収する(産生細胞は培地中に粒子を排出しており、ある時点で培地中の粒子濃度が粒子を回収するのに最適である)。上清は、遠心分離、超遠心分離、沈殿、限外ろ過、および/またはクロマトグラフィー等、当技術分野における任意の公知の方法によって精製し得る。いくつかの実施形態において、上清を最初にろ過し、例えば、0.45孔径のポリフッ化ビニリデン親水性膜(Millipore Millex-HV)または0.8μm孔径の混合セルロースエステル親水性膜(Millipore Millex-AA)を通して、1μmより大きい粒子を除去する。ろ過後、例えば、超遠心分離を、例えば、1℃~5℃の温度で80,000~100,000xgの速度で1~2時間、または1℃~5℃の温度で8,000~15,000gの速度で10~16時間使用して、上清をさらに精製および濃縮し得る。この遠心分離ステップの後、heVLPを遠心分離物(ペレット)の形態で濃縮し、これを所望の濃度に再懸濁し、形質導入促進試薬と混合し、緩衝剤交換に供しても、またはそのまま使用してもよい。いくつかの実施形態において、heVLP含有上清をろ過し、沈殿させ、遠心分離し、濃縮溶液に再懸濁し得る。例えば、ポリエチレングリコール(PEG)、例えばPEG8000、またはheVLP表面タンパク質または膜構成要素に結合する抗体ビーズコンジュゲートを使用して、粒子を沈殿させることができる。精製された粒子は安定しており、4℃で1週間まで、または-80℃で数年間保存しても、評価可能な活性を失わない。
heVLP粒子は、ポリエチレンイミン(PEI)ベースのプラスミドのトランスフェクションを使用して、HEK293T細胞によって産生された。PEIはポリエチレニミン25kD 直鎖(Polysciences #23966-2)である。「PEI MAX」のストック溶液を作製するために、1gのPEIを1Lの事前に約80℃まで加熱したエンドトキシンフリーのdH2Oに添加し、室温まで冷却した。この混合物を10NのNaOHの添加によってpH7.1に中和し、0.22μmのポリエーテルスルホン(PES)でろ過滅菌した。PEI MAXは-20℃で保存する。
HEK 293T細胞を、VEGF部位#3を標的とした、spCas9と融合したPLC PH、spCas9と融合したhGAGKcon、またはspCas9と融合したhArcを含むT1heVLPによって形質導入した。T1heVLPは、hENVW(左図)またはhENVFRD(右図)のいずれかによってシュードタイプ化された。遺伝子改変はアンプリコン配列決定によって測定した。粒子の精製および濃縮は、PVDFろ過および100,000xg、2時間の超遠心分離によって行った。結果を図3に示す。重要なことに、HERV由来のGAG(hGAGKcon)が産生細胞において単独で過剰発現しておらず、その際、効率的な送達は達成されなかった。
本発明をその詳細な説明と併せて説明してきたが、前述の説明は、添付の特許請求の範囲によって定義される本発明の範囲を説明することを目的としており、本発明を限定するものではないことは理解されたい。他の局面、利点、および改変は、以下の特許請求の範囲の範囲内である。
Claims (25)
- 操作されたヒト由来ウイルス様粒子(heVLP)であって、heVLPが、外側に、1つまたは複数のHERV由来のENV/糖タンパク質を有するリン脂質二重層を含む膜;膜の内側のheVLPコアにHERV由来のGAGタンパク質、およびheVLPのコアに配置されたカーゴを含み、前記カーゴがヒト内在性GAGまたは他の細胞膜動員ドメインと融合しており、heVLPが非ヒトのgagおよび/またはpolタンパク質を含まない、前記heVLP。
- 前記カーゴが、治療用もしくは診断用タンパク質、または治療用もしくは診断用タンパク質をコードする核酸、または低分子である、請求項1に記載のheVLP。
- 前記カーゴが遺伝子編集試薬である、請求項1に記載のheVLP。
- 前記遺伝子編集試薬が、ジンクフィンガー(ZF)、転写活性化因子様エフェクター(TALE)、および/またはCRISPRベースのゲノム編集もしくは調節タンパク質;ジンクフィンガー(ZF)、転写活性化因子様エフェクター(TALE)、および/またはCRISPRベースのゲノム編集もしくは調節タンパク質をコードする核酸;またはCRISPRベースのゲノム編集もしくは調節タンパク質を含むリボヌクレオタンパク質複合体(RNP)を含む、請求項1に記載のheVLP。
- 前記遺伝子編集試薬が、表2、3、4および5に列挙するタンパク質から選択される、請求項4に記載のheVLP。
- 前記遺伝子編集試薬が、CRISPRベースのゲノム編集または調節タンパク質を含み、前記heVLPが、前記CRISPRベースのゲノム編集または調節タンパク質に結合し、それを標的配列に誘導する1つまたは複数のガイドRNAをさらに含む、請求項4に記載のheVLP。
- 前記カーゴが、好ましくは表6に示される、ヒト内在性GAGまたは他の細胞膜動員ドメインとの融合体を含む、請求項1~6のいずれか一項に記載のheVLP。
- カーゴ分子を標的細胞、任意にインビボまたはインビトロの細胞に送達する方法であって、前記カーゴ分子を含む、請求項1に記載のheVLPと前記細胞を接触させることを含み、好ましくは前記カーゴ分子が生体分子および/または化学物質である、前記方法。
- 1つまたは複数のカーゴ分子を含むheVLPを産生する方法であって、
1つまたは複数のHERV由来のエンベロープタンパク質、1つまたは複数のHERV由来のGAGタンパク質、および1つまたは複数のカーゴ分子を発現する細胞であって、ヒトゲノムにおいてコードされるgagタンパク質またはヒトゲノムに見出されるgagタンパク質に由来するコンセンサス配列によってコードされるgagタンパク質を除いて、gagおよび/またはpolタンパク質を発現せず細胞を用意すること、ならびに
細胞がheVLPを産生するような条件で細胞を維持すること
を含む、前記方法。 - 産生されたheVLPを回収し、任意に精製および/または濃縮することをさらに含む、請求項9に記載の方法。
- 前記カーゴ分子が、治療用もしくは診断用タンパク質、または治療用もしくは診断用タンパク質をコードする核酸、または低分子の治療剤または診断剤である、請求項9に記載の方法。
- 前記カーゴ分子が遺伝子編集試薬である、請求項9に記載の方法。
- 前記遺伝子編集試薬が、ジンクフィンガー(ZF)、転写活性化因子様エフェクター(TALE)、および/またはCRISPRベースのゲノム編集もしくは調節タンパク質;ジンクフィンガー(ZF)、転写活性化因子様エフェクター(TALE)、および/またはCRISPRベースのゲノム編集もしくは調節タンパク質をコードする核酸;またはCRISPRベースのゲノム編集もしくは調節タンパク質を含むリボヌクレオタンパク質複合体(RNP)を含む、請求項9に記載の方法。
- 前記遺伝子編集試薬が、表2、3、4、および5に列挙するタンパク質から選択される、請求項13に記載の方法。
- 前記遺伝子編集試薬が、CRISPRベースのゲノム編集または調節タンパク質を含み、前記heVLPが、前記CRISPRベースのゲノム編集または調節タンパク質に結合し、それを標的配列に誘導する1つまたは複数のガイドRNAをさらに含む、請求項13に記載の方法。
- 前記カーゴ分子が、好ましくは表6に示される、ヒト内在性GAGまたは他の細胞膜動員ドメインとの融合体を含む、請求項9~15のいずれか一項に記載の方法。
- 1つまたは複数のHERV由来のエンベロープタンパク質、
1つまたは複数のHERV由来のGAGタンパク質、および
好ましくは、ヒト内在性GAGまたは他の細胞膜動員メントドメインと融合している、カーゴ分子
を組み合わせて発現し、
非ヒトGAGタンパク質を発現しない、細胞。 - 前記カーゴ分子が、治療用もしくは診断用タンパク質、または治療用もしくは診断用タンパク質をコードする核酸である、請求項17に記載の細胞。
- 前記カーゴ分子が遺伝子編集試薬である、請求項17に記載の細胞。
- 前記遺伝子編集試薬が、ジンクフィンガー(ZF)、転写活性化因子様エフェクター(TALE)、および/またはCRISPRベースのゲノム編集もしくは調節タンパク質;ジンクフィンガー(ZF)、転写活性化因子様エフェクター(TALE)、および/またはCRISPRベースのゲノム編集もしくは調節タンパク質をコードする核酸;またはCRISPRベースのゲノム編集もしくは調節タンパク質を含むリボヌクレオタンパク質複合体(RNP)を含む、請求項17に記載の細胞。
- 前記遺伝子編集試薬が、表2、3、4、および5に列挙するタンパク質から選択される、請求項20に記載の細胞。
- 前記遺伝子編集試薬が、CRISPRベースのゲノム編集または調節タンパク質を含み、前記heVLPが、前記CRISPRベースのゲノム編集または調節タンパク質に結合し、それを標的配列に誘導する1つまたは複数のガイドRNAをさらに含む、請求項20に記載の細胞。
- 前記カーゴ分子が、好ましくは表6に示される、ヒト内在性GAGまたは他の細胞膜動員ドメインとの融合体を含む、請求項17~22のいずれか一項に記載の細胞。
- 初代のまたは安定的なヒト細胞株である、請求項17~23のいずれか一項に記載の細胞。
- ヒト胎児腎(HEK)293細胞、HEK293 T細胞、またはBeWo細胞である、請求項24に記載の細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962861186P | 2019-06-13 | 2019-06-13 | |
US62/861,186 | 2019-06-13 | ||
PCT/US2020/037740 WO2020252455A1 (en) | 2019-06-13 | 2020-06-15 | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022536364A true JP2022536364A (ja) | 2022-08-15 |
JPWO2020252455A5 JPWO2020252455A5 (ja) | 2024-02-27 |
Family
ID=73782119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021573607A Pending JP2022536364A (ja) | 2019-06-13 | 2020-06-15 | 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法 |
Country Status (6)
Country | Link |
---|---|
US (4) | US20220259617A1 (ja) |
EP (1) | EP3982989A4 (ja) |
JP (1) | JP2022536364A (ja) |
CN (1) | CN114258398A (ja) |
CA (1) | CA3143327A1 (ja) |
WO (1) | WO2020252455A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10392674B2 (en) | 2015-07-22 | 2019-08-27 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
AU2019343045A1 (en) | 2018-09-18 | 2021-05-13 | Vnv Newco Inc. | ARC-based capsids and uses thereof |
JP2022526908A (ja) | 2019-03-19 | 2022-05-27 | ザ ブロード インスティテュート,インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
WO2022133266A1 (en) * | 2020-12-18 | 2022-06-23 | The Broad Institute, Inc. | Evolution of botulinum neurotoxin proteases |
CN113337506B (zh) * | 2021-06-21 | 2023-01-03 | 珠海乐维再生医学科技有限公司 | CRISPRi介导的抑制瘢痕形成的外泌体及其制备方法和应用 |
WO2023102550A2 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Compositions and methods for efficient in vivo delivery |
GB202118946D0 (en) | 2021-12-23 | 2022-02-09 | Evox Therapeutics Ltd | Engineered extracellular vesicles with improved cargo delivery |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9304239D0 (en) * | 1993-03-01 | 1993-04-21 | British Bio Technology | Viral particles |
US6136598A (en) * | 1997-05-09 | 2000-10-24 | Fred Hutchinson Cancer Research Center | Mus dunni endogenous retroviral packaging cell lines |
CA2501301A1 (en) * | 2005-03-18 | 2006-09-18 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Human endogenous foamy retrovirus and uses thereof |
WO2010040023A2 (en) * | 2008-10-03 | 2010-04-08 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods and compositions for protein delivery |
US8835149B2 (en) * | 2012-12-06 | 2014-09-16 | Exxonmobil Research And Engineering Company | DGAT genes comprising pleckstrin homology domains and methods of use for triglyceride production in recombinant microorganisms |
US10968253B2 (en) * | 2015-10-20 | 2021-04-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
WO2017106822A1 (en) * | 2015-12-17 | 2017-06-22 | The Penn State Research Foundation | Paramyxovirus virus-like particles as protein delivery vehicles |
GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
JP7231226B2 (ja) * | 2016-11-07 | 2023-03-01 | ユニバーシティ オブ マサチューセッツ | 顔面肩甲上腕型筋ジストロフィーのための治療標的 |
JP7277466B2 (ja) * | 2017-09-01 | 2023-05-19 | インプラザー エー・ペー・エス | 疾患の予防および/または治療における使用のためのワクチン |
CN111225682A (zh) * | 2017-10-20 | 2020-06-02 | 吉尼松公司 | 合胞素用于将药物和基因靶向递送至肺组织的用途 |
CA3099497A1 (en) * | 2018-05-15 | 2019-11-21 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
-
2020
- 2020-06-15 JP JP2021573607A patent/JP2022536364A/ja active Pending
- 2020-06-15 EP EP20822926.0A patent/EP3982989A4/en active Pending
- 2020-06-15 CN CN202080057410.3A patent/CN114258398A/zh active Pending
- 2020-06-15 CA CA3143327A patent/CA3143327A1/en active Pending
- 2020-06-15 WO PCT/US2020/037740 patent/WO2020252455A1/en active Application Filing
- 2020-06-15 US US17/617,490 patent/US20220259617A1/en active Pending
-
2023
- 2023-07-13 US US18/351,674 patent/US20240011049A1/en active Pending
- 2023-07-13 US US18/351,800 patent/US20240018544A1/en active Pending
- 2023-07-13 US US18/351,689 patent/US20240011050A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3982989A4 (en) | 2023-07-19 |
WO2020252455A1 (en) | 2020-12-17 |
EP3982989A1 (en) | 2022-04-20 |
US20240011049A1 (en) | 2024-01-11 |
US20240011050A1 (en) | 2024-01-11 |
CA3143327A1 (en) | 2020-12-17 |
CN114258398A (zh) | 2022-03-29 |
US20240018544A1 (en) | 2024-01-18 |
US20220259617A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022536364A (ja) | 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法 | |
Kamimura et al. | Advances in gene delivery systems | |
US8569065B2 (en) | Compositions and methods for the delivery of biologically active RNAs | |
Li et al. | Non-viral strategies for delivering genome editing enzymes | |
US11851671B2 (en) | Programmable assembly of virus composites for receptor-targeted gene delivery | |
JP2022548308A (ja) | カーゴを標的細胞に送達するための組成物及び方法 | |
AU2012358181A1 (en) | Compositions and methods for the delivery of biologically active RNAs | |
US20230227793A1 (en) | Enhanced virus-like particles and methods of use thereof for delivery to cells | |
Whitley et al. | Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing | |
J Glover | Artificial viruses: exploiting viral trafficking for therapeutics | |
Lu et al. | CRISPR/Cas9 delivery strategies with engineered extracellular vesicles | |
Wang et al. | Current status of gene therapy for hepatocellular carcinoma, with a focus on gene delivery approaches | |
JP2023531506A (ja) | トンネルナノチューブ細胞および生体分子の送達のためのその使用方法 | |
Kwak et al. | Advanced approaches to overcome biological barriers in respiratory and systemic routes of administration for enhanced nucleic acid delivery to the lung | |
US20230332181A1 (en) | Conjugate systems and methods of use thereof | |
Mittal et al. | Challenges and Opportunities of Gene Therapy in Cancer | |
Chan et al. | Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications | |
Agirre et al. | Strategies for improving the systemic delivery of oncolytic adenoviruses and plasmids: Potential application of non-viral carriers | |
Khalil et al. | Literature Review: Historical and Current Developments in Gene Delivery Technologies Relevant to Therapeutic Use | |
CN114555191A (zh) | 用于表达嵌合受体的递送载体和颗粒及其使用方法 | |
Stoneham | Investigation into the entry and intracellular trafficking of a bacteriophage-derived gene therapy vector | |
Pedro | Molecular Determinants of Virus-Like Nanoparticle Assembly in vitro and in Animal Cell Culture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20221215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230613 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240215 |